$COSMJun 11, 2026, 7:31 PMAI processed
Cosmos Health (COSM) signs LOI to acquire GMP manufacturer Doc Pharma; says deal will be accretive
AI Summary
Cosmos Health (NASDAQ: COSM) entered a non-binding LOI to acquire Doc Pharma S.A., a GMP‑licensed ~59,000 sq ft European drug manufacturer that Cosmos says brings ~ $24M of assets, a three‑year average of ~$6.7M in annual revenue and ~$3.2M in average annual gross profit; the company says the acquisition would deepen vertical integration, expand capacity and be immediately accretive to margins and cash flow. Doc Pharma is a related‑party; the transaction requires independent director review, a fairness opinion, a PCAOB audit, shareholder approval and final due diligence, so completion and the touted benefits are not guaranteed.
Positives
- Adds an estimated ~$24M asset base to Cosmos' balance sheet
- Brings a three‑year average of ~$6.7M revenue and ~$3.2M gross profit, which Cosmos expects to be immediately accretive
- Acquires a GMP‑licensed ~59,000 sq ft facility with broad dosage capabilities and multiple certifications (GMP, ISO, Kosher, Halal) and regional registrations
Negatives
- Non‑binding LOI — transaction is not finalized and is subject to due diligence
- Target is a related‑party, triggering independent review, fairness opinion, PCAOB audit and shareholder approval (governance risk)
- Financial figures are three‑year averages converted from euros and are subject to final verification and potential variability